Celltrion Inc stock (KR7068270008): US biosimilar launch and facility acquisition

Celltrion Inc launched STEQEYMA, a Stelara biosimilar, in the US in March 2025 after FDA approval. The company also acquired a biopharma facility from Eli Lilly, expanding US manufacturing.

Celltrion Inc, a leading South Korean biopharmaceutical firm, marked a key milestone for US investors with the March 2025 US launch of STEQEYMA (ustekinumab-stba), its biosimilar to Johnson & Johnson's Stelara, following FDA approval. This entry targets the lucrative autoimmune disease market. Additionally, Celltrion acquired a biopharmaceutical manufacturing facility in the US from Eli Lilly and Company, bolstering its domestic production capabilities, as noted in Simply Wall St as of May 2026 and openPR as of 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Celltrion, Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: South Korea
• Core markets: US, Europe, Asia
• Key revenue drivers: Biosimilars, monoclonal antibodies
• Home exchange/listing venue: Korea Exchange (068270)
• Trading currency: KRW

Celltrion Inc: core business model

Celltrion Inc develops and manufactures biologic medicines, with a focus on biosimilars to blockbuster drugs. The company produces monoclonal antibodies for autoimmune and inflammatory conditions, including Remsima (infliximab) and Truxima (rituximab). Its pipeline emphasizes high-value therapeutics for global markets, supported by in-house R&D and manufacturing. Celltrion holds a strong position in the biosimilars space, competing with originators through cost-effective alternatives.

Listed on the Korea Exchange under ticker 068270, Celltrion serves US investors via its growing presence in the NYSE-listed biosimilar market. The firm's strategy centers on regulatory approvals in key regions like the FDA, enabling direct competition in the $100B+ biologics sector.

Main revenue and product drivers for Celltrion Inc

Biosimilars drive over 90% of Celltrion's revenue, with key products like Yuflyma (adalimumab) and Vegzelma (bevacizumab) contributing significantly. In 2025, the US launch of STEQEYMA targets the ustekinumab market, projected to exceed $10B annually, according to pipeline updates in openPR 2026. The Eli Lilly facility acquisition enhances US production capacity for these drugs.

Revenue growth stems from expanded approvals and partnerships. Celltrion's manufacturing investments, including the new US site, reduce reliance on imports and support scalability for US demand.

Industry trends and competitive position

The global biosimilars market is expanding rapidly, valued at $40B in 2025 and forecasted to reach $100B by 2030, driven by patent expirations on drugs like Stelara. Celltrion competes with Samsung Bioepis, Sandoz, and Amgen, leveraging vertical integration from development to commercialization. Its US facility acquisition positions it favorably against import-dependent rivals.

For US investors, Celltrion offers exposure to biotech innovation with lower valuations typical of Korean-listed firms compared to US peers.

Why Celltrion Inc matters for US investors

Celltrion provides US investors access to Asia's biosimilar boom via its KRX listing, with products directly challenging US blockbusters. The STEQEYMA launch and Lilly facility deal signal deeper US integration, potentially boosting ADR interest or future listings. Amid rising US healthcare costs, biosimilars like those from Celltrion support affordability initiatives.

Risks and open questions

Celltrion faces patent litigation risks from originators like J&J, alongside manufacturing scale-up challenges at the new US site. Currency fluctuations (KRW/USD) and regulatory delays could impact earnings. Competition intensifies as more biosimilars enter the market.

Conclusion

Celltrion Inc's US biosimilar launch and facility expansion highlight its strategic push into the American market, offering growth potential amid biosimilar trends. While execution risks persist, these developments enhance its global footprint. Investors track upcoming earnings and pipeline progress for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.